Ocular Therapeutix announced the appointment of Christopher White as Senior Vice President, Head of Business and Corporate Development.
“We are thrilled to welcome Chris to the Ocular team to oversee business and corporate development,” Antony Mattessich, President and Chief Executive Officer, said in a company news release. “Chris joins us in the midst of a long and distinguished career that spans Big Pharma, management consulting, and both private and public biotech. I believe the momentum at Ocular has never been better with the recent launch of Dextenza and, with a highly productive platform and pipeline, it is the right time to be building out our business development capabilities. We are incredibly fortunate to have attracted someone of Chris’ talent and stature in the industry and we look forward to his immediate and ongoing contributions.”
Christopher White brings over 25 years of operations management, business development, partnering and strategic planning experience in the biopharmaceutical industry. Prior to joining Ocular, Mr. White was the Chief Operating Officer at Silver Creek Pharmaceuticals, a private Bay Area biotechnology company focused on the development of novel regenerative medicines. Prior to his work at Silver Creek, Mr. White held senior leadership positions in the biotechnology industry, including Chief Business Officer at both Entasis Therapeutics and AMAG Pharmaceuticals, where he was responsible for business and corporate development, portfolio management, and strategic planning. Prior to entering the biotechnology industry, Mr. White worked as a partner at management consulting firms Accenture and A.T. Kearney, where he advised pharmaceutical and biopharmaceutical clients on a broad range of commercial and strategic issues. Mr. White holds a Bachelor of Science degree in Chemical Engineering from Tufts University and a Master of Business Administration from Columbia University.